Cheung Kong Holdings
Search results
Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, commercialisation, marketing and sale of health and agriculture-related products...
- Careers
Thanks for visiting us at Careers. We are looking for...
- Sustainability
Sustainability - CK Life Sciences Int’l., (Holdings) Inc.
- Corporate Profile
Bearing the mission of improving the quality of life, CK...
- Annual & Interim Reports
Annual & Interim Reports - CK Life Sciences Int’l.,...
- Board of Directors
Tighe is an Independent Non-executive Director of CK...
- Pharmaceutical Research
Melanoma. Seviprotimut-L is a melanoma cancer vaccine being...
- Contact Us
Address: 2 Dai Fu Street, Tai Po Industrial Estate, Hong...
- Board Committees
Board Committees - CK Life Sciences Int’l., (Holdings) Inc.
- Careers
CK Life Sciences International (Holdings) Inc. (Chinese: 長江生命科技集團有限公司), or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products.
Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in products and assets which fall into three core categories – nutraceuticals, pharmaceuticals & diagnostics, and agriculture-related.
Annual Report 2007 Third Quarter Report 2007 Half-year Report 2007 First Quarter Report 2007
Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and...
Find the latest CK Life Sciences Int'l., (Holdings) Inc. (0775.HK) stock quote, history, news and other vital information to help you with your stock trading and investing.
Nov 1, 2023 · HONG KONG SAR – Media OutReach – 1 November 2023 – CK Life Sciences Int’l., (Holdings) Inc. is presenting preclinical data for its investigational dual-antigen cancer vaccines, co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed death-ligand 1), on November 4 at the 2023 Society for Immunotherapy of Cancer (SI...
